Codex Genetics
Unraveling your uniqueness
Unraveling your uniqueness
Codex Genetics Codex Genetics, founded in 2013 Q1 by scientists specialized in genomics and bioinformatics, aims to personalize cancer treatment through its cutting-edge technology. The company's flagship product, GENESIS, is a cancer genetics test developed using next generation sequencing. Codex's growing pharmacogenomics database provides valuable insights into individual tumor causes, enabling tailored treatment for cancer patients. Their clinical pharmacogenomics platform uses individual genetic information to inform treatment options and predict drug responses. By offering two clinically actionable genetic tests for cancer and other FDA-approved diseases, Codex supports clinicians in providing personalized medication in the realm of "Precision Medicine." The company received a $41.25K Seed Round investment on 01 January 2014 from Cyberport Hong Kong. With its focus on biotechnology, Codex Genetics is headquartered in Hong Kong S.a.r.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $41.25K | 1 | Cyberport Hong Kong | 01 Jan 2014 |
No recent news or press coverage available for Codex Genetics.
We care about your data, and we'd love to use cookies make your experience better.